ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2206 entries already.
First emergency approvals of vaccines and antibody drugs in less than a year are great achievements of modern biotechnology in our battle against the COVID-19 pandemic, but we still have no efficient therapeutics to cure severe COVID-19. Millions of lives remain at risk until we control the pandemic, and what if we will never reach herd immunity? Waiting for others to do the job cannot be the strategy, as well as betting only on vaccines.
The B.1.1.7 variant of SARS-CoV-2, which was first identified in the UK, may be associated with an increased risk of death, a Nature study suggests.
Roche to acquire GenMark Diagnostics, Inc., to access platform to test for broad range of pathogens with one patient sample.
While media reports suggest AstraZeneca’s COVID-19 jab might have caused blot clots, the EMA didn’t confirm a causal relationship.
Swiss Roche AG has missed the primary endpoint in the REMDACTA trial in patients with severe COVID-19 pneumonia.
Africa produces less than 1% of the human vaccines it uses. To effectively respond in time of outbreaks and pandemics, Africa must expand its vaccine development and production capabilities to cater for its growing population. Successfully establishing such an industry at scale is a multifaceted endeavour to create an enabling environment. This article highlights key factors and considerations for establishing local vaccine manufacturing.
The current debates regarding vaccine production and logistics have also made it clear even to the layman: Pharmaceutical production depends on cold. Temperatures below -80?°C are just as common as the requirement to freeze precursors such as blood plasma within a specified time period. Refrigeration specialists with pharmaceutical know-how are in demand for these challenging tasks.
Danish sustainable crop protection company, BioPhero AS, has raised $17m in Series A funding led by DCVC Bio.
German researchers have presented a new method to assess on-target and off-target effects of CRISPR-Cas nucleases or TALENs.
EMA’s human medicines committee has started a rolling review of Sputnik V, a COVID-19 vaccine developed by Russia’s Gamaleya National Centre of Epidemiology and Microbiology.